Clinical trial results give new hope for children with rare gliomas Dr. Kamal Kant Kohli25 Nov 2023 10:30 AM ISTA collaboration of researchers, led by UCL and Great Ormond Street Hospital, have published successful results from a Phase II clinical trial for the...
Novartis secures USFDA nod for Tafinlar plus Mekinist for pediatric brain cancer Ruchika Sharma17 March 2023 2:35 PM ISTLow grade glioma is the most common pediatric brain cancer.
Novartis gets CDSCO Panel nod to market anticancer drug Trametinib and Dabrafenib for additional indication Dr. Divya Colin1 Jan 2023 5:45 PM ISTNew Delhi: In a significant development, the drug major Novartis has got a go ahead from the Subject Expert Committee (SEC) functional under the...
USFDA nod to Novartis Tafinlar plus Mekinist for solid tumors with gene mutation Ruchika Sharma23 Jun 2022 2:47 PM ISTBRAF V600E is the most common type of BRAF mutation, accounting for up to 90% of BRAF-mutant cancers.
Novartis Tafinlar, Mekinist combination shows promise in childhood brain cancer Ruchika Sharma7 Jun 2022 3:22 PM ISTThe trial only included those who were found to have a mutation known as BRAF V600, a genetic contributor in about 15% to 20% of pediatric LGG cases.
Novartis Healthcare gets CDSCO panel nod to market anti cancer drug Dabrafenib Susmita Roy19 Feb 2022 5:49 PM ISTNew Delhi: In a significant development, pharmaceutical major Novartis Healthcare has got a go ahead from the Subject Expert Committee (SEC) of the...
Health Bulletin 22/November/2021 Roshni Dhar22 Nov 2021 5:51 PM ISTHere are Top Health stories of the dayPatient dies of Hemorrhagic shock post LSCS: Consumer Court holds medical negligence by doctor, hospital,...
Novartis gets CDSCO panel nod to study Dabrafenib, Trametinib FDC Medical Dialogues Team21 Nov 2021 11:45 AM ISTNew Delhi: In a significant development, pharma major Novartis has got a go ahead from the Subject Expert Committee (SEC) functional under the Central...
